PRLD — Prelude Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $223.53m
- -$9.41m
- 37
- 33
- 64
- 41
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -27.6 | -56.9 | -112 | -115 | -122 |
Depreciation | |||||
Non-Cash Items | 0.856 | 5.59 | 23.6 | 29.5 | 24.1 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.667 | 4.62 | 3.63 | 0.932 | -10.5 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -25.7 | -46.2 | -83.5 | -83.7 | -107 |
Capital Expenditures | -0.78 | -0.621 | -2.32 | -3.02 | -3.51 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | -261 | 84.7 | -31.1 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.78 | -0.621 | -264 | 81.7 | -34.6 |
Financing Cash Flow Items | — | -0.012 | -0.303 | 0 | -0.017 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 29.7 | 246 | 165 | 0.815 | 136 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 3.28 | 199 | -182 | -1.22 | -5.31 |